» Articles » PMID: 36135836

Understanding the Polyamine and MTOR Pathway Interaction in Breast Cancer Cell Growth

Overview
Journal Med Sci (Basel)
Specialty General Medicine
Date 2022 Sep 22
PMID 36135836
Authors
Affiliations
Soon will be listed here.
Abstract

The polyamines putrescine, spermidine and spermine are nutrient-like polycationic molecules involved in metabolic processes and signaling pathways linked to cell growth and cancer. One important pathway is the PI3K/Akt pathway where studies have shown that polyamines mediate downstream growth effects. Downstream of PI3K/Akt is the mTOR signaling pathway, a nutrient-sensing pathway that regulate translation initiation through 4EBP1 and p70S6K phosphorylation and, along with the PI3K/Akt, is frequently dysregulated in breast cancer. In this study, we investigated the effect of intracellular polyamine modulation on mTORC1 downstream protein and general translation state in two breast cancer cell lines, MCF-7 and MDA-MB-231. The effect of mTORC1 pathway inhibition on the growth and intracellular polyamines was also measured. Results showed that polyamine modulation alters 4EBP1 and p70S6K phosphorylation and translation initiation in the breast cancer cells. mTOR siRNA gene knockdown also inhibited cell growth and decreased putrescine and spermidine content. Co-treatment of inhibitors of polyamine biosynthesis and mTORC1 pathway induced greater cytotoxicity and translation inhibition in the breast cancer cells. Taken together, these data suggest that polyamines promote cell growth in part through interaction with mTOR pathway. Similarly intracellular polyamine content appears to be linked to mTOR pathway regulation. Finally, dual inhibition of polyamine and mTOR pathways may provide therapeutic benefits in some breast cancers.

Citing Articles

Heterogeneity in polyamine metabolism dictates prognosis and immune checkpoint blockade response in hepatocellular carcinoma.

Pan J, Lin Z, Pan Q, Zhu T Front Immunol. 2025; 16:1516332.

PMID: 39981249 PMC: 11839726. DOI: 10.3389/fimmu.2025.1516332.


Single-cell expression and immune infiltration analysis of polyamine metabolism in breast cancer.

Zhang X, Guo H, Li X, Tao W, Ma X, Zhang Y Discov Oncol. 2024; 15(1):666.

PMID: 39549127 PMC: 11569334. DOI: 10.1007/s12672-024-01524-w.


Single-cell omics and machine learning integration to develop a polyamine metabolism-based risk score model in breast cancer patients.

Zhang X, Guo H, Li X, Tao W, Ma X, Zhang Y J Cancer Res Clin Oncol. 2024; 150(10):473.

PMID: 39441216 PMC: 11499360. DOI: 10.1007/s00432-024-06001-z.


Extracellular putrescine can augment the epithelial-mesenchymal transition of gastric cancer cells by promoting MAL2 expression by elevating H3K27ac in its promoter region.

Bi C, Li C, Xing L, Lu Z, Liu H, Hu T Am J Cancer Res. 2024; 14(6):2805-2822.

PMID: 39005660 PMC: 11236783. DOI: 10.62347/BEUV4081.


Impaired polyamine metabolism causes behavioral and neuroanatomical defects in a mouse model of Snyder-Robinson syndrome.

Akinyele O, Munir A, Johnson M, Perez M, Gao Y, Foley J Dis Model Mech. 2024; 17(6).

PMID: 38463005 PMC: 11103582. DOI: 10.1242/dmm.050639.


References
1.
Wallace H, Duthie J, Evans D, Lamond S, Nicoll K, Heys S . Alterations in polyamine catabolic enzymes in human breast cancer tissue. Clin Cancer Res. 2000; 6(9):3657-61. View

2.
Martin T, Dennis M, Gordon B, Kimball S, Jefferson L . mTORC1 and JNK coordinate phosphorylation of the p70S6K1 autoinhibitory domain in skeletal muscle following functional overloading. Am J Physiol Endocrinol Metab. 2014; 306(12):E1397-405. PMC: 4059989. DOI: 10.1152/ajpendo.00064.2014. View

3.
Pegg A . The function of spermine. IUBMB Life. 2014; 66(1):8-18. DOI: 10.1002/iub.1237. View

4.
Rousseau D, Kaspar R, Rosenwald I, Gehrke L, Sonenberg N . Translation initiation of ornithine decarboxylase and nucleocytoplasmic transport of cyclin D1 mRNA are increased in cells overexpressing eukaryotic initiation factor 4E. Proc Natl Acad Sci U S A. 1996; 93(3):1065-70. PMC: 40031. DOI: 10.1073/pnas.93.3.1065. View

5.
Eroglu Z, Tawbi H, Hu J, Guan M, Frankel P, Ruel N . A randomised phase II trial of selumetinib vs selumetinib plus temsirolimus for soft-tissue sarcomas. Br J Cancer. 2015; 112(10):1644-51. PMC: 4430716. DOI: 10.1038/bjc.2015.126. View